A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer

被引：0
|
作者：
Clarke, S. J. [1 ,2 ,3 ]
Smith, J. T. [1 ,2 ,3 ]
Gebbie, C. [1 ,2 ,3 ]
Sweeney, C. [1 ,2 ,3 ]
Olszewski, N. [1 ,2 ,3 ]
机构：
[1] Alder Biopharmaceut Inc, Bothell, WA USA
[2] Sydney Canc Ctr, Sydney, NSW, Australia
[3] Univ Adelaide, Adelaide, SA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3025
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer
    Bayliss, Trevor J.
    Smith, Jeff T.
    Schuster, Michael
    Dragnev, Konstantin H.
    Rigas, James R.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (12) : 1663 - 1668
  • [2] ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial.
    Schuster, M.
    Rigas, J. R.
    Orlov, S. V.
    Milovanovic, B.
    Prabhash, K.
    Smith, J. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized double-blind safety and efficacy trial.
    Rigas, J. R.
    Schuster, M.
    Orlov, S. V.
    Milovanovic, B.
    Prabhash, K.
    Smith, J. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Pegram, Mark D.
    Borges, Virginia F.
    Ibrahim, Nuhad
    Fuloria, Jyotsna
    Shapiro, Charles
    Perez, Susan
    Wang, Karen
    Stark, Franziska Schaedli
    Luck, Nigel Courtenay
    BREAST CANCER RESEARCH, 2009, 11 (05)
  • [5] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer
    Mark D Pegram
    Virginia F Borges
    Nuhad Ibrahim
    Jyotsna Fuloria
    Charles Shapiro
    Susan Perez
    Karen Wang
    Franziska Schaedli Stark
    Nigel Courtenay Luck
    Breast Cancer Research, 11
  • [6] Clinical Efficacy of Anti-IL-6 Receptor Monoclonal Antibody Tocilizumab in Patients with Neuromyelitis Optica
    Araki, Manabu
    Matsuoka, Takako
    Aranami, Toshimasa
    Nakamura, Masakazu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Yamamura, Takashi
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 911 - 912
  • [7] Phase I trial and pharmacokinetic (PK) analysis of depsipeptide in patients with advanced cancer
    Marshall, JL
    Dahut, WL
    Rizvi, N
    Wainer, IW
    Chassaing, C
    Figuiera, M
    Hawkins, MJ
    ANNALS OF ONCOLOGY, 1998, 9 : 123 - 123
  • [8] Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab in three patients with neuromyelitis optica
    Araki, M.
    Aranami, T.
    Matsuoka, T.
    Nakamura, M.
    Okamoto, T.
    Murata, M.
    Miyake, S.
    Yamamura, T.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 417 - 417
  • [9] Tocilizumab (Anti-IL-6 Receptor Antibody) and Intravenous Immunoglobulin (IVIG) in Difficult To Desensitize Patients: Phase I/II Trial
    Vo, Ashley
    Kim, Jua
    Kim, Irene
    Jordan, Stanley
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15 : 49 - 49
  • [10] A phase I and pharmacokinetic (PK) study of the rebeccamycin analog NSC 655649 in patients with advanced cancer
    Eckhardt, SG
    Kuhn, J
    Rizzo, J
    Sharma, S
    Campbell, E
    Ivey, P
    Weiss, G
    Hammond, L
    Kraynak, M
    Von Hoff, DD
    Rowinsky, EK
    ANNALS OF ONCOLOGY, 1998, 9 : 66 - 66
12345